ArticleThe Journal of infectious diseases2013
Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.
Article in The Journal of infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 109 citations in OpenAlex.
- Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling.Antimicrobial agents and chemotherapy · 2015Trial
- The impact of TcdB conformational dynamics on vaccination against Clostridioides difficile.PLoS pathogens · 2026Article
- Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- A single amino acid substitution determines susceptibility ofFrontiers in cellular and infection microbiology · 2026Article
- The monoclonal antibody AZD5148 confers broad protection against TcdB-diverse Clostridioides difficile strains in mice.PLoS pathogens · 2025Article
- Article
- Enhanced immunogenicity of a Clostridioides difficile TcdB vaccine adjuvanted with a synthetic dual-TLR ligand adjuvant.NPJ vaccines · 2025Article
- Mechanisms ofFrontiers in cellular and infection microbiology · 2025Review
- Synthetic niclosamide-loaded controlled-release nanospheres with high solubility and stability exerting multiple effects againstFrontiers in microbiology · 2025Article
- Clostridioides difficile toxin B subverts germinal center and antibody recall responses by stimulating a drug-treatable CXCR4-dependent mechanism.Cell reports · 2024Article
- Prosurvival Pathway Protects From Clostridioides difficile Toxin-Mediated Cell Death.The Journal of infectious diseases · 2024Article
- Synthetic microbial consortia for the treatment of Clostridioides difficile infection in mice model.Microbial biotechnology · 2023Article
- Biofilm Formation ofMicroorganisms · 2023Review
- Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects againstWorld journal of gastrointestinal pathophysiology · 2023Article
- AAV-mediated delivery of actoxumab and bezlotoxumab results in serum and mucosal antibody concentrations that provide protection from C. difficile toxin challenge.Gene therapy · 2023Article
- Make It LessGenes · 2022Review
- Antibiotic resistance and genomic features ofPeerJ · 2022Article
- Application of recombinant antibodies for treatment ofFrontiers in immunology · 2022Review
- Translational Aspects of the Immunology of Clostridioides difficile Infection: Implications for Pediatric Populations.Journal of the Pediatric Infectious Diseases Society · 2021Review
- Editorial for the Special Issue:Microorganisms · 2021Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundA dramatic increase in morbidity and mortality from Clostridium difficile infection (CDI) due to the recent emergence of virulent, antibiotic-resistant strains has led to a search for alternatives to antibiotics, including vaccines and immune-based therapy that target the 2 key toxins-TcdA and TcdB.
methodsWe investigated the efficacy of specific human monoclonal antibodies (HuMab) and alpaca polyclonal antibodies against each toxin separately and in combination in the gnotobiotic piglet model of CDI. Additionally, the HuMab and polyclonal antibodies were exploited to investigate the precise contribution of each toxin to systemic and/or gastrointestinal (GI) tract disease.
resultsOur results indicate that TcdB is an important virulence factor associated with GI and systemic pathology. Administration of anti-TcdB antibody alone or with anti-TcdA protected 100% of piglets from development of systemic CDI and minimized GI lesions. Conversely, 100% of piglets administered only anti-TcdA developed severe GI and systemic disease, with 67%-83% fatality, faring worse than placebo-treated control animals.
conclusionsThese results highlight the importance of TcdB in the pathogenesis of CDI and the effectiveness of TcdB-specific antibody in treating CDI. However, the results raise new questions regarding the nature of TcdA interaction with therapeutic antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.